Gosset Androgen Receptor Splice Variant 7 Overview
Androgen receptor splice variant 7 (AR-v7) is a splice variant of the androgen receptor (AR) that lacks the C-terminal ligand-binding domain (LBD). AR-v7 is constitutively active and drives gene transcription independently of ligand binding. It is frequently detected in castration-resistant prostate cancer (CRPC) and associated with resistance to therapies targeting the androgen receptor pathway, particularly those inhibiting the LBD such as enzalutamide and abiraterone. Detection of AR-V7 is important for guiding therapy selection in metastatic CRPC.
Mechanism of Action
AR-v7 is constitutively active and drives transcription independently of ligand binding, bypassing the mechanism of action of drugs targeting the ligand-binding domain of the full-length androgen receptor.
Biological Functions
Disease Associations
Safety Considerations
- Resistance to androgen receptor-targeted therapies (enzalutamide, abiraterone)
- Poor prognosis in CRPC patients
- Therapeutic challenges in targeting the constitutively active variant.
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| AR-V7 mRNA or protein levels (detection methods include immunohistochemistry and molecular assays) |